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Aminoglycoside antibiotics are a central component of
the treatment of pulmonary exacerbations of cystic
ﬁbrosis (CF) and slow the decline in lung function which
ultimately causes the death of most patients. The
prognosis of CF has improved, and thus side effects of
treatments have become increasingly important.
Observational studies suggest that the morbidity from
side effects of aminoglycosides is disturbingly common,
and that aggressive treatment may lead to more side
effects. This review of the current literature on side
effects of aminoglycosides considers the
pathophysiological mechanisms, epidemiology and risk
factors, investigation of side effects and preventative
strategies. Treatments which have shown early promise
are identiﬁed and areas of future research are discussed.
INTRODUCTION
Cystic ﬁbrosis (CF) is the most common life-
limiting autosomal recessive disorder in the
Caucasian population with approximately 7000
affected individuals in the UK.
1 A mutation in the
CF gene leads to a defective or absent CF trans-
membrane conductance regulator (CFTR) which, in
most patients, ultimately leads to bronchiectasis
and chronic infection with Pseudomonas aeruginosa.
Intravenous aminoglycosides are used for exacer-
bations owing to their efﬁcacy against Paeruginosa.
Patients often require several courses of intravenous
antibiotics per year. The survival of patients with
CF has improved, and side effects of treatment have
become increasingly important.
We review the current literature on the side
effects of aminoglycosides commonly used to treat
pulmonary exacerbations of CF. The major side
effects of aminoglycosides are kidney injury,
hearing impairment and vestibular toxicity.
RENAL TOXICITY IN CYSTIC FIBROSIS
Acute kidney injury
Studies vary in their deﬁnition of toxicity, but
approximately 5e10% of (non-CF) adult patients
receiving an aminoglycoside have a signiﬁcant
increase in serum creatinine.
2 Although toxicity is
an aminoglycoside class effect, experimental data
suggest that gentamicin is more toxic than tobra-
mycin and amikacin.
3 A quantitative overview of
randomised controlled trials (RCTs) reached
broadly the same conclusions.
4
The tenacity of infection and altered pharmaco-
kinetics in CF necessitate long courses of high-dose
antibiotics.
5 Since the introduction of regular
3-monthly intravenous antibiotic therapy for
patients with chronic P aeruginosa in Danish CF
clinics in the mid-1970s,
6 the management of
pulmonary infection in CF has become more
aggressive. However, case reports of acute kidney
injury (AKI; previously termed acute renal failure)
associated with aminoglycoside antibiotics in CF
were not published until the late 1990s.
The ﬁrst report of AKI secondary to intravenous
aminoglycosides in CF
7 was followed by several
other cases and mini-series. Inhaled tobramycin has
also been implicated.
8 Bertenshaw et al
9 conducted
a national survey of AKI in patients with CF (AKI
was pragmatically deﬁned as an increased serum
creatinine for age) and found that the incidence was
4.6e10.5/10000 CF patients/year. A subsequent
caseecontrol study
10 established that an amino-
glycoside in the previous week increased the risk of
AKI >80-fold. Risk factors for renal impairment
(including CF-related diabetes, non-steroidal anti-
inﬂammatory drugs and acute dehydration) were
strongly associated with AKI (OR 24.0). Exposure
to gentamicin in the previous year was associated
with AKI while exposure to tobramycin was not.
Chronic kidney disease
Regular courses of aminoglycoside antibiotics may
cause subclinical kidney damage leading to chronic
kidney disease (CKD). This can manifest at the
level of the glomerulus (causing decreased glomer-
ular ﬁltration rate, GFR) and the tubules (causing
altered excretion of electrolytes). The stages of
CKD are shown in table 1.
Pederson et al
11 described a series of 46 patients
aged 10e35 years who had received a mean of 20
courses of tobramycin and used 24 h urinary
creatinine clearance to assess renal function. The
cumulative dose of tobramycin was not related to
the creatinine clearance; 39% of patients had
reduced GFR (deﬁned as <96 ml/min/1.73 m
2).
However, 24 h urinary creatinine collections are
known to be unreliable, especially in children.
The largest study investigating CKD in CF was
reported by Al-Aloul et al.
12 Creatinine clearance
was measured in 24 h urine collections in 80 adult
patients with CF chronically infected with P aeru-
ginosa. Multiple urinary collections per patient were
taken to ensure accuracy. The median number of
courses of antibiotics per patient was 40 (range
1e130); 42% of patients had a creatinine clearance
<80 ml/min/1.73 m
2. Creatinine clearance declined
with increasing number of antibiotic courses
(r¼0.59). Colistin was not associated with
decreased kidney function when administered with
a b-lactam but, when administered with an
aminoglycoside, the two agents together were
associated with more kidney damage than an
aminoglycoside alone. Creatinine clearance can be
predicted using equations such as the modiﬁcation
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Reviewof diet in renal disease (MDRD) and CockrofteGault formulae.
In this study, the CockrofteGault formula to predict creatinine
clearance performed poorly and missed cases of CKD.
Investigators have used biomarkers to obtain indirect evidence
of subclinical kidney injury in many research settings.
N-acetyl-b-D-glucosaminidase (NAG), one of the best charac-
terised biomarkers, is a proximal tubular enzyme excreted in the
urine in response to kidney damage. Paediatric patients with CF
administered intravenous tobramycin have increased urinary
NAG levels which remain elevated weeks after treatment.
13
However, patients taking inhaled gentamicin also have increased
urinary NAG levels,
14 suggesting that the test is highly sensitive
and may not indicate clinically important renal damage.
The literature on direct comparisons of alternative intrave-
nous agents in CF is complex. Comparing the relative toxicities
of tobramycin and colistin in an observational study, Ether-
ington et al
15 found that tobramycin was associated with a larger
acute rise in NAG. However, increased baseline NAG levels
(perhaps indicating chronic toxicity) prior to antibiotics was
associated with a higher cumulative colistin dose rather than
a cumulative tobramycin dose. In comparison, Al-Aloul et al
12
found that, when administered with a non-nephrotoxic agent,
colistin was cumulatively less nephrotoxic than tobramycin.
Symptomatic hypomagnesaemia associated with amino-
glycosides in CF is well documented.
16 Holben et al described
a series of 192 patients with CF with a prevalence of hypo-
magnesaemia of 3%.
17
Mechanism of renal toxicity
Despite extensive study, the exact mechanisms of aminoglyco-
side nephrotoxicity remain elusive. Care must be taken when
interpreting animal models of aminoglycoside kidney injury as
these studies often use doses higher than those used in clinical
practice. Recent technologies allow new methods of exploring
mechanisms including metabolic and transcriptome analysis,
18
proteomic and microarray techniques.
19
Results from gentamicin (the most extensively studied
aminoglycoside) are often extrapolated to other aminoglyco-
sides. After glomerular ﬁltration, approximately 15% of a ﬁltered
load of an aminoglycoside is reabsorbed into the kidney.
20 The
uptake of aminoglycosides into the proximal tubule (a key step
in the pathogenesis of kidney injury) is saturable, although the
level of this effect depends upon the aminoglycoside.
21 Excretion
of aminoglycosides from this compartment is a slow process,
taking many days.
22
Testing the hypothesis that uptake of drugs into the renal
cortex is saturable in humans is difﬁcult but has been studied in
a series of studies in patients scheduled for nephrectomy.
23
Different dosing schedules of aminoglycosides were used and
kidney cortical drug concentrations were directly measured after
nephrectomy. The renal cortical concentration of amikacin and
gentamicin was lower after a single dose of amikacin compared
with the same dose infused over 24 h, despite the area under the
curve (AUC) of serum concentration versus time being higher.
Thus, uptake of these drugs is saturable in vivo in humans.
Although there was a trend to higher cortical levels when
tobramycin was continuously infused, statistical signiﬁcance
was not achieved but the numbers of patients were limited.
23
Aminoglycosides can affect the nephron at the level of the
glomerulus and the tubule, although the latter has been more
extensively studied. Insights into the potential mechanisms of
decreased glomerular ﬁltration have been gained from ultra-
structural studies.
24 Exposure of the glomerulus to gentamicin
decreases the surface area available for ultraﬁltration, the base-
ment membrane increases in thickness, the glomerulus changes
in shape and the number and diameter of fenestrae decrease.
The effect of gentamicin on the proximal tubular cell is
summarised in ﬁgure 1. After uptake, a number of cellular
processes are activated, culminating in apoptosis. This contrib-
utes to loss of the renal tubular epithelium and thus kidney
dysfunction but, conversely, shedding and urinary excretion of
apoptotic bodies may excrete aminoglycosides.
Changes in proximal tubular function are manifested as
proteinuria, glycosuria and urinary loss of brush border enzymes.
Altered tubular function has been attributed to multiple mech-
anisms including alteration in production of membrane trans-
porters
18 and decreased parathyroid hormone-mediated cAMP
formation and subsequent decreased magnesium uptake.
25
Strategies to reduce nephrotoxicity of aminoglycosides
Many groups are currently investigating strategies to reduce the
nephrotoxicity of aminoglycosides. Potential approaches include
blocking tubular uptake, reducing the formation of reactive
oxygen species (ROS), inhibiting cellular signalling leading to
apoptosis, and enhancing the ability of the kidney to regenerate.
These were outlined 10 years ago but have not yet been trans-
lated into clinical practice.
26
Strategiestoreducenephrotoxicityalreadyexist.Attentiontothe
dose prescribedandmonitoring serumlevelsare paramount inthis.
Patients with CF who develop AKI are more likely to have received
gentamicininthe preceding yearthantobramycinwhencompared
with controls,
10 so tobramycin is the preferred aminoglycoside in
CF. Avoidance of risk factors such as concurrent non-steroidal anti-
inﬂammatory drugs and dehydration would seem prudent.
Manipulation of the dosing regimen provides a cost-effective
and simple method of reducing kidney injury. Given the saturable
uptake of aminoglycosides, it follows that a single daily dose
wouldbeexpectedtobelessnephrotoxicthanthesamedailydose
in three divided doses (see ﬁgure 2). The TOPIC study, a large
randomised trial of tobramycin for patients with CF, established
that there is equal efﬁcacy with a single daily dosing regimen as
with a multiple daily dosing regimen,
27 a ﬁnding conﬁrmed in
a subsequent meta-analysis.
28 In the paediatric group receiving
a single daily dose, theserum creatinine level decreased during the
course of treatment compared with a rise in the group receiving
three divided doses. In further support of renal safety, in the once
dailyarmtheriseinNAGwas33%lessthaninthegroupreceiving
a three times daily regimen in both adults and children.
The pharmacokinetics of aminoglycosides are complicated by
a circadian rhythm in elimination. In the once daily group of the
TOPIC study, most of whom received their antibiotics in the
evening, there was a lower elimination rate of tobramycin than
in the three times daily group.
29 There may be a diurnal varia-
tion in renal clearance of the drug, with decreased clearance
occurring at night. This would lead to increased exposure of the
kidneys to aminoglycoside during the course of the illness if the
Table 1 Grades of chronic kidney disease categorised












In general, serum biochemical anomalies may occur in grade II,
symptoms appear in grade III, become increasingly severe in grade IV
and renal replacement therapy is required in grade V.
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Reviewdrug is administered at night compared with the morning. This
hypothesis requires testing in clinical trials.
OTOTOXICITY
Ototoxicity in patients with CF
Estimates of the prevalence of ototoxicity in patients with CF
depend on the methods used and deﬁnitions of hearing impair-
ment. The most straightforward measurement of hearing
impairment is the pure tone audiogram (PTA). In this, the
patient listens to a series of different frequencies and the quietest
sound level at each frequency which can be reliably heard is
established (the ‘threshold’ level, measured in decibels (dB)).
A selection of the numerous studies reporting PTAs in CF
which clearly report the population studied, the deﬁnition of
hearing impairment and the sample prevalence is given in
table 2. A frequently cited report of the prevalence of hearing
impairment is that of Mulheran et al.
30 They studied 70 patients
recruited from a CF clinic and, using the deﬁnition of $2
thresholds of >20 dB or one of >25 dB, they found an overall
prevalence of hearing impairment of 17%.
Oto-acoustic emissions (OAE; sounds generated by the cochlea
during hearing) and distortion product OAEs (DPOAE; in which
the ear generates a sound of a third pitch when presented
simultaneously with two sounds of differing pitch) have been
proposed as an early screening tool for cochlear damage. Patients
with CF can have a normal PTA but abnormal oto-acoustic
emissions which may be an indicator of early toxicity.
31
Several DPOAE parameters can be measured including ampli-
tude (volume) and latency (the amount of time for a pair of tones
to travel from the ear canal to the cochlea, generate a DPOAE and
return this tone back to the ear canal). The numerous methods of
calculatingthelatencycomplicatetheliterature.PatientswithCF
exposed to high cumulative doses of tobramycin have alterations
in latencies.
32 The relevance of these ﬁndings (eg, early detection
of ototoxicity) has yet to be fully understood.
Mechanism of ototoxicity
While the mechanisms of otoxicity and nephrotoxicity are
similar, there are several key differences. Ototoxicity and neph-
rotoxicity are separate events, so patients with ototoxicity need
not have nephrotoxicity and vice versa. Megalin is responsible
for the uptake of aminoglycosides into the proximal tubular cells
but is not found in the hair cells of the organ of Corti.
33 After
aminoglycoside administration, the concentration in the hair
cells of the organ of Corti is static over several weeks (the kidney
gradually excretes it).
34
Aminoglycoside ototoxicity causes degeneration of hair cells
in the organ of Corti,
35 predominantly in the basal turn which is
required to sense high-frequency sounds. Extracellular signalling
normally causes inﬂux of calcium into hair cells. After genta-
micin exposure, calcium inﬂux no longer occurs in basal hair
cells but persists in apical hair cells.
36 Thus, a clear relationship
exists between the clinical features of high-frequency hearing
loss, pathophysiological and histological ﬁndings.
As in the kidney, interactions between iron and aminoglyco-
sides leading to the formation of ROS play a role in toxicity.
Administering iron in animal models increases ototoxicity.
37
Gentamicin causes upregulation of intermediaries in the
apoptosis signalling pathways between the cell surface and the
nucleus. Blocking these and other intermediaries in the apoptosis
cascade causes reduced apoptosis in response to gentamicin.
38
Several mitochondrialribosomal mutationsareassociated with
ototoxicity. The most well known is the A1555G mutation in
the MT-RNR1 mitochondrial gene described by Prezant et al.
39
Figure 1 Potential cellular mechanism
of toxicity. This diagram summarises the
major themes of the literature, much of
which is in vitro work and so has to be
interpreted as a model. Gentamicin
enters the tubular cell via the multiligand
receptor megalin (shown in blue) and
then uptake is via a clatharin-coated pit.
Gentamicin passes in a retrograde
manner via the lysosomes, Golgi and
endoplasmic reticulum into the
cytoplasm where it forms complexes
with ironwhich catalyse the formation of
reactive oxygen species (ROS). In the
lysosomes,gentamicincausesreleaseof
the pro-apoptotic cathepsins and, in the
endoplasmic reticulum, gentamicin
causes release of the pro-apoptotic
stressproteinvonHippeleLindaubinding
protein 1 (VBP1). Cytosolic gentamicin
either directly or indirectly (via ROS)
causes therelease of cytochrome C from
themitochondria,akeystepinapoptosis.
ROS cause an increase in the gene
expression of oxidative stress-inducible
genes, stress-inducible chaperones and
oxido-reductive enzymes. Gentamicin
may have intracellular effects without
entry to the cell. It can cause a rapid
increaseinintracellularCa
2+andanearly
increase in the anti-apoptosis and
pro-proliferative signals Akt and Erk; this
may be mediated by the membrane Ca
2+
receptor CaR (shown in purple).
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ReviewThis confers a high risk of ototoxicity when an individual with
the mutation is exposed to aminoglycosides. Conrad et al
40
studied an unselected group of 153 adults with CF; 42.2% were
found to have “mild” ototoxicity and 8.6% had “moderate to
severe ototoxicity”. The investigators sequenced portions of the
MT-RNR1 gene of all the patients and found ﬁve with poly-
morphisms previously proposed as mutations associated with
hearing impairment; three of these patients had hearing impair-
ment, which was severe in two cases. They also identiﬁed vari-
ation in 16 other positions, ﬁve of whom had hearing loss.
The cost-effectiveness of screening for the A1555G mutation
in patients with CF has been modelled.
41 Making the assump-
tions of a low prevalence of the mutation (0.086%), a high false
positive screening rate, and that clinicians would switch anti-
biotic therapy to a less effective agent in response to a positive
screening result (thus increasing the risk of mortality), this
model suggested that screening all patients with CF for A1555G
was not cost-effective. However, at the time epidemiological
data used for the prevalence of the mutation were less than that
found in the more recent large studies of Bitner-Glindzicz et al
(0.19%) and Vandebona et al (0.21%).
42 43
Strategies to prevent ototoxicity
Measures to reduce the generation or effects of ROS due to
aminoglycosides have been extensively investigated and there
are several promising avenues of research. A brief report of
a randomised trial of aspirin versus no aspirin for 14 days in 195
patients treated with gentamicin showed a lower incidence of
hearing impairment with aspirin (3% vs 13%; p¼0.013).
44
Additionally, a randomised trial comparing N-acetylcysteine
(NAC) versus no NAC in adult patients on dialysis treated with
gentamicin reported fewer cases of hearing impairment in the
NAC group (20% vs 55%, p¼0.022).
45 Both of these preliminary
results require conﬁrmation but are nevertheless encouraging.
VESTIBULOTOXICITY
Vestibulotoxicity due to aminoglycosides is secondary to damage
of the hair cells in the vestibular system and does not necessarily
occur with cochleotoxicity. Early symptoms of vestibulotoxicity,
often insidious in onset, include vague dizziness and feeling
light-headed. These may easily go unrecognised. Partial recovery
can occur but can take several months.
There is little published literature regarding the prevalence of
vestibulotoxicity in CF owing to the difﬁculty of deﬁning and
measuring it, particularly in children. A number of possible tests
are available to screen for vestibular dysfunction, many of which
are technically challenging for the non-specialist. Two studies
have systematically screened for vestibulotoxicity in CF.
Thomsen et al reported a study of 53 patients with a mean age
of 11.8 years who had received a mean of 3.2 courses of tobra-
mycin.
46 A differential caloric test was performed and, in this
series, no patients had an abnormal result.
Scheenstraetal
47reportedadetailedinvestigationof23patients
with CF in the Netherlands, 30% of whom had peripheral
vestibular loss diagnosed by electronystagmography (often
consideredthegoldstandardtest).Ofthreepatientswhoreported
symptoms which suggested horizontal vestibular function loss
such as rotatory dizziness, one patient had severe bilateral
vestibular dysfunction. There was no association between
cumulative exposure to tobramycin and vestibulotoxicity.
Comparison of the aminoglycoside exposure of the two studies
isdifﬁcultasthestudybyThomsenetalreportedmeancoursesof
antibioticswhilethestudybyScheenstraetalreportedcumulative
area under the curve. It is likely that the patients in the study by
Scheenstra et al had a higher cumulative exposure to tobramycin.
Figure 2 Effects of saturable uptake on kidney cortical accumulation in
single daily versus three times daily dosing. In three times daily dosing
(shown in red), all of the area under the curve (AUC; red shaded area)
contributes to the uptake of the aminoglycoside into the kidney cortex.
However, above a certain threshold (indicated by the arrow), the receptor-
mediated uptake of the aminoglycoside is saturated and serum
concentrations above this level do not contribute to the uptake of
aminoglycosideintotherenalcortex.Asthisthresholdisexceededinsingle
daily dosing (shown in green), a proportion of the single daily dose AUC
does not contribute to renal uptake. Thus, the area below this threshold
contributes to renal uptake (the green area in single daily dosing). As the
greenareaissmallerthantheredarea,therenaluptakeinsingledailydosing
is thought to be lower than with the three times daily dosing regimen.
Table 2 Selected studies investigating the prevalence of hearing loss in cystic ﬁbrosis (CF)
Author Study methods Deﬁnition of HI Results
Forman-Franco et al, 1979
49 PTA using frequencies 250, 500, 1000,
2000, 4000, 8000 Hz. Recruited from a CF
clinic (n¼80)
Air conduction thresholds for $2
frequencies >25 dB
1/80 (1%) had HI
Pedersen et al, 1987
11 PTA (frequency range 125e8000 Hz).
High-frequency audiogram from
4000e20000 Hz. All patients had chronic
P aeruginosa (n¼42)
Threshold increased by $15 dB in one or
both ears at two or more adjacent
frequencies
2/42 patients (5%) had high-frequency HI.
Both patients had normal thresholds
<8000 Hz
Mulheran et al, 2001
30 PTA over frequencies 250e8000 Hz.
High-frequency PTA over
10000e16000 Hz (n¼70)
$2 thresholds in either ear of $20 dB or
one frequency of $25 dB over the
frequency range 250e8000 Hz
17% had HI
Conrad et al, 2008
40 Annual audiometric assessment of
patients at two CF clinics with PTA over
frequency range 1000e8000 Hz. DPOAE
were measured over the frequency range
841e7996 Hz (n¼153)
Either one PTA threshold >25 dB or
abnormal DPOAE thresholds
50.8% had abnormal hearing
DPOAE, distortion product otoacoustic emissions; HI, hearing impairment; PTA, pure tone audiogram.
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Patients with CF have a large lifetime exposure to multiple
medications. Aggressive treatment with intravenous antibiotics
slows the progression of lung disease, decreases morbidity and
delays mortality, with a cost of an increased risk of side effects.
Minimising the risk of side effects is of paramount importance
within the ‘ﬁrst, do no harm’ principle.
Recent single-centre studies have suggested that the preva-
lence of side effects such as chronic kidney disease, ototoxicity
and vestibulotoxicity are disturbingly high in the CF population.
If these ﬁndings are conﬁrmed, clinicians will need strategies to
minimise the risk of toxicity. CKD has implications for lung
transplantation as it is well recognised that further nephrotox-
icity occurs after transplantation.
Currently, there are limited options for monitoring the early
signs of toxicity. Serum creatinine-based formulae are poor at
predicting renal function in the CF population; a biomarker which
reliably predicts GFR (or screens patients for renal impairment) is
urgently needed in the clinical setting. Similarly, once the PTA has
become abnormal due to aminoglycoside ototoxicity, hearing is
not expected to improve. Further research evaluating the role of
DPOAEs as an early marker of cochlear damage is required.
Some strategies have already been widely adopted, such as
once daily aminoglycosides, the use of tobramycin rather than
gentamicin and careful monitoring of drug levels. Other
approaches such as the optimum time of day of administration
of antibiotics, screening for mutations which predispose to
ototoxicity and the use of aspirin and NAC in patients with CF
require careful consideration and further research.
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